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Abstract
In this chapter, we describe relevant aspects of immunoglobulin Y (IgY) technology for 
Toxoplasma gondii applications, including comparison of avian IgY antibody with mam‐
malian IgG antibody, egg yolk IgY production and isolation procedures, important 
applications for IgY antibody, and state of the art and perspectives for IgY‐technology 
in T. gondii studies. T. gondii is a worldwide public health problem. IgY‐technology pro‐
vides an alternative antibody (IgY) to mammalian Immunoglobulin G (IgG) antibody. 
IgY‐technology involves the chicken immunization, yolk IgY isolation, antibody charac‐
terization, and purified IgY application to several kinds of methods. Immunized chicken 
transfers a specific IgY from blood to egg yolk. Phylogenetic distance between chickens 
and mammals influences the generation of antibody repertoires recognizing an antigen 
profile. IgY is not bound to rheumatoid factor or mammalian complement protein and 
thus avoids the false‐positive results. Yolk IgY isolation is carried out by simple pro‐
cedures that are accessible for any laboratory and, also, for IgY isolation at large‐scale 
production. IgY‐technology provides antibodies for proteomic studies, diagnostic assays, 
and immunotherapy. Although IgY‐technology is promising, there is a reduced number 
of investigations with IgY and T. gondii. Future perspectives involve the use of IgY‐tech‐
nology for the screening of new T. gondii antigens for diagnostics, therapy, or vaccine, 
development of innovative techniques for toxoplasmosis diagnostics and may be an 
immunotherapy for toxoplasmosis.
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1. Introduction
Toxoplasma gondii is the toxoplasmosis agent in human and animals and is a worldwide pub‐
lic health problem. Alternative approach that offers possibility to improve diagnostics, treat‐
ment, or control of toxoplasmosis should be accepted as a protective approach to hosts at risk 
of infection by T. gondii. Immunoglobulin Y (IgY)‐technology was designed in 1980s with 
the aim to reduce the suffering procedures to obtain a high‐quality antibody, replace animal 
model for antibody production and refine the kind of applications for purified antibodies. 
IgY‐based antibody production derived from chicken egg yolk antibody is named immuno‐
globulin Y (IgY). Hens transfer IgY from blood to egg yolk protecting their offspring. Isolation 
of yolk IgY avoids bleeding the chicken and reduces the number of painful procedures. Hens 
can lay approximately one egg each day during a period of 2 years. IgY antibody is functional 
and is equivalent to mammal IgG antibody. Both avian and mammalian antibodies have struc‐
ture similarity. They have two identical light chains and two identical heavy chains bounded 
to each other by disulfide bonds. In the amino terminal extremity, they have the fragment 
antigen‐binding (Fab). In the carboxy terminal region, they have the fragment crystallizable 
(Fc) that is associated to biological antibody functions as interaction with cells or molecules 
from immune system. Virtually, any substance can be the target of an antibody response and 
the response to even a single epitope comprises many different antibody molecules, each with 
a subtly different specificity for the epitope and a unique affinity, or binding strength. The 
total number of antibody specificities available for an individual is known as the antibody 
repertoire. The number of antibody specificities present at a particular time is limited by the 
total number of B cells in an individual, as well as by each individual’s previous encounters 
with antigens. Albeit, they are equivalent in function and structure, the phylogenetic dis‐
tance and the way to generate antibody specificities produce difference in epitope recognition 
repertoire between avian and mammalian host. Additionally, modifications in amino acid 
sequence of IgY antibody result in advantages, comparing to IgG, as follows: IgY does not 
bound to rheumatoid factor, Fc receptor or mammalian complement proteins that can avoid 
false‐positive results, and many others. Isolation of yolk antibodies begins by removing lipid 
fraction from yolk and obtaining a water‐soluble fraction, and further procedures includ‐
ing salt‐based precipitation, gel filtration, or affinity chromatography provide a high‐purity 
IgY‐enriched fraction. Purified IgY antibody can be applied to several kinds of techniques 
including screening new antigens by phage display, enzymatic or florescence immunoassays, 
diagnostics, and, also, passive immunization for therapy against gastrointestinal pathogens 
in humans and animal hosts. Future perspective using IgY‐technology as a tool for T. gondii 
investigation should include development of new antigen libraries as an innovative source 
of possible targets for diagnostics, therapy, or vaccination. In addition, create new diagnostic 
platforms for diagnosing T. gondii infection. Finally, the potential protective effect of IgY to be 
used in prevention or toxoplasmosis therapy by passive immunization should be explored. In 
this chapter, we describe relevant aspects of IgY‐technology to T. gondii investigations, includ‐
ing comparing avian IgY antibody with mammalian IgG antibody, egg yolk IgY production 
and isolation procedures, important applications for IgY antibody, and state of the art and 
perspectives for IgY technology in T. gondii studies.
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2. Overview in IgY technology
2.1. Comparing avian IgY antibody with mammalian IgG antibody
2.1.1. General history
In the early 1893, Klemperer published his observation that there must be neutralizing pro‐
teins (i.e., antibodies) in the yolk of eggs laid by immunized chickens. In 1980s, when ani‐
mal welfare came to be regarded as a serious ethical claim for the scientific community, the 
extraction of specific antibodies from the egg yolk was considered as an alternative to the 
blood‐taking methods. In this context, phylogenetic distance between chickens and mam‐
mals, mechanisms of antibody repertoire diversification, and the way in which chickens 
deposit IgY immunoglobulin in the egg yolk provide a number of advantages compared to 
mammals as animal model for antibody production. In an additional manner, the one‐step 
purification of antibodies from egg yolk in large amounts provides a virtually continuous 
supply; the epitope repertoire recognition of IgY antibodies potentially grants access to new 
specificities; the absence of cross‐reactivity with mammalian epitopes avoids false‐positive 
interference and improves the performance of immunological assays. The generation and 
application of avian antibodies has caused a surge of interest in a wide variety of applications 
within the life sciences [1].
2.1.2. Structure characterization of IgY and IgG antibodies
Structurally, avian IgY antibody is similar to mammalian IgG antibody (Figure 1). Two 
identical light chains and two identical heavy chains that are bounded by disulfide bonds 
compose the antibody’s molecular structure [2]. Both chains are formed by the sequences 
of amino acids (approximately 110 amino acids) named domains which are numerically 
ordered from the amino terminal region (NH
3
+) to the carboxy terminal region (COO−). The 
amino terminal domain, named variable domains, presents a variable amino acid composi‐
tion sequence by the occurrence of mutational events during the B lymphocyte‐produced 
immune response. For both light chain and heavy chain, variable domains (VL and VH) 
have three regions with higher variation rate in amino acid sequence named complemen‐
tarity determining region (CDR). Complementarity determining regions (CDRs) are com‐
pletely bounded to epitopes (antigenic determinant) during a specific humoral response. In 
the direction to carboxy terminal extremity, after the variable domain, there are the constant 
domains. The light chain has one constant domain (CL); however, the number of constant 
domains for the heavy chain varies with antibody isotypes. IgY heavy chain, named upsi‐
lon (Greek letter υ), has four constant domains (CH), and IgG heavy chain, named gamma 
(Greek letter γ), has three domains (CH) [2, 3].
The fragment antigen‐binding (Fab) is positioned in amino terminal extremity and is com‐
posed by the entire light chain (VL and CL) and both VH and CH1 domains. The IgY fragment 
crystallizable (Fc) is formed by CH2, CH3, and CH4 domains and IgG Fc by the hinge region 
is formed by CH2 and CH3 domains. There was proposed that IgY CH2 domain must be 
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converted to IgG hinge region, which provides a higher mobility to the mammalian Fab than 
to its avian equivalent. Regarding heavy chain, the chicken has two other classes of antibod‐
ies (Immunoglobulin M [IgM], heavy chain µ, and IgA, heavy chain α) and mammals have 
other four classes of antibodies (IgM, heavy chain µ; Immunoglobulin A [IgA], heavy chain α; 
Immunoglobulin E [IgE], heavy chain ε; and Immunoglobulin D [IgD], heavy chain σ) [2, 3].
2.1.3. Generation of antigen recognizing repertoire in chicken and mammals
In the genome of a germ‐line cell, the genetic information for an immunoglobulin (Ig) poly‐
peptide chain is contained in multiple gene segments scattered along a chromosome. During 
the development of bone marrow‐derived lymphocytes, these gene segments are assembled 
by recombination that leads to the formation of a complete gene [4]. The vertebrate B‐cell 
repertoire is capable of generating up to 10(9) different antibody molecules. To generate 
diversity, mammals depend on combinatorial and functional variations that occur during the 
gene rearrangement events to produce complete heavy and light chain Ig genes. This gene 
rearrangement process goes continuously in the bone marrow, where each developing B cell 
assembles a unique heavy and light chain Ig gene from families of functional V (variable), D 
(diversity), and J (joining) gene segments. In contrast, chickens have only single functional V 
and J segments for the heavy and light chain loci, and chicken Ig gene rearrangement occurs 
only during a brief period of embryonic development. A specialized organ involved in avian 
B‐cell development, the bursa of Fabricius, provides the microenvironment necessary for the 
amplification of B cells that have undergone productive Ig gene rearrangements. Within the 
bursa, B cells also acquire somatic diversity among the rearranged V gene segments of the 
Figure 1. Schematic general structure of the egg yolk antibody (IgY) and the mammalian IgG antibody.
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heavy and light chain Ig loci. Somatic diversification of chicken V gene segments occurs by 
intrachromosomal gene conversion, a DNA recombination process which involves unidirec‐
tional transfer of nucleotide sequence blocks from the families of V region pseudogenes into 
the functional rearranged VH and VL genes [5].
2.1.4. Molecular characterization of IgY and IgG antibodies
Phylogenetic studies have shown that the IgY antibody, homolog of mammalian IgG, has 
similarities with both mammalian IgG and IgE antibodies. IgY is the predominant isotype 
in sera, produced after IgM in the primary antibody response, and it is the main isotype 
produced in the secondary immune response. IgY has different biochemical properties from 
those of mammalian IgG antibodies and shares homology while functioning with them. Due 
to the lack of the hinge region, IgY has limited flexibility to its Fab resulting in to precipi‐
tate antigens at physiological salt concentrations. Chicken IgY in serum is monomeric, with 
molecular weight (MW) 165–206 kDa, the mean serum concentration average 5–7 mg/mL and 
in yolk approximately 25 mg/mL [2]. Mammalian IgG is the Ig found in highest concentration 
in blood and plays a major role in antibody‐mediated defenses. It has a MW of about 180 kDa. 
Its serum level is approximately 8–16 mg/mL in human and 17–27 mg/mL in cattle [3]. The 
amount of antibodies obtainable from rabbit is approximately 200 mg, IgG/bleeding (40 mL 
blood) with 5% of specific antibody, and from chicken is approximately 100 mg/egg (5–7 eggs/
week) with 2–10% of specific antibody. IgY sampling is not invasive, which confers advantage 
on IgG; also, yolk antibody does not interfere with rheumatoid factor or activate mammalian 
complement [1].
2.2. IgY production
The IgY technology–based layout to produce polyclonal antibodies is displayed in Figure 2. 
First step is the chicken immunization followed by the yolk IgY extraction, the antibody char‐
acterization, and finally IgY applications in various kinds of assays. Chickens are a suitable 
model to produce IgY by immunization with nucleic acid [6], protein [7], lipid, and carbo‐
hydrates [8]. In addition, an immune humoral response must be elicited by immunization 
with recombinant proteins [9] or peptides [10]. To improve the specific IgY response it is 
demanded the use of adjuvants like Freund’s adjuvants for immunization procedures, which 
is the most frequently used adjuvant. Intramuscularly way is a common way for chicken 
immunization to produce specific IgY. Alternatively, subcutaneous way provides satisfactory 
amounts of specific antibody [1].
2.3. IgY purification
Regarding its constitution, yolk can be viewed as an oil‐water emulsion with a watery portion 
containing proteins and a dispersal portion of so‐called yolk‐granules and lipid‐drops [11]. 
The concentration and distribution of immunoglobulins Y (IgY) in the serum and egg are 6 
and 25 mg/ml, respectively. The concentrations of specific antibodies in the yolk are similar to 
the antibody profile of the serum. To isolate yolk IgY, distinct procedures may be used alone 
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or in combination according to the following criteria: amount, purity, and biological activity. 
The yolk antibody extraction begins by separating yolk and egg white. After removal of the 
vitellin membrane, the yolk is put into a measuring cylinder. The next steps in IgY extrac‐
tion are devoted to removing the lipid content and obtaining a water soluble phase (WSP) 
antibodies enriched [12]. The consequent purification procedures vary widely in type and 
combination and from laboratory to laboratory. The degree of IgY purity depends on desired 
application; for example, for oral administration, the whole yolk can be used, and on the other 
hand, for a reagent, isolated IgY from the mixture of yolk molecules is necessary [1].
2.3.1. Removing lipid from yolk
A high quality removing lipid method is the first step to efficiently isolate IgY antibodies from 
egg yolk. Several natural gums, as carrageenan and xanthan gum, were found to be effective 
for removal of yolk lipoprotein as a precipitate, resulting in a water‐soluble fraction with very 
low lipid concentration [13, 14]. Optionally, organic solvents (chloroform) have been used as a 
mean to remove yolk lipid content at the initial step of IgY isolation [1, 14]. The water‐dilution 
method is a widespread procedure for the yolk lipid removal, which provides IgY‐enriched 
water‐soluble fraction [14–16].
2.3.2. Isolating IgY by precipitation methods
The extraction of yolk antibodies by the use of polyethylene glycol precipitation (PEG, MW 
6000) was, firstly, developed by Polson et al. [17]. The IgY‐extraction by means of PEG‐pre‐
cipitation is very cost‐effective and results in highly specific antibody with stable titers up 
Figure 2. General layout to produce specific IgY antibodies. From immunization with different antigens added to 
adjuvants, isolating egg yolk antibody to IgY applications.
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to 1:1,000,000 [18]. Afterwards, PEG 6000 was widely accepted as a standard procedure. 
Pulverized PEG 6000 is added to WSP until the final concentration of 3.5% is stirred, and the 
protein precipitate is pelleted by first centrifugation. Finally, PEG is added to supernatant 
until it brings the final concentration to 12%. The mixture is stirred thoroughly and a second 
centrifugation PEG method can result in a high IgY antibody concentration per egg; however, 
it may not be homogeneous when analyzed by SDS‐polyacrylamide gel electrophoresis [19]. 
To improve the quality of extraction, after PEG 12% precipitation, saturated ammonium sul‐
fate solution can be added to IgY enriched fraction [20]. Additionally, by following precipita‐
tion procedures, the IgY antibodies may be further purified by DEAE cellulose ion‐exchange 
column chromatography [21] or ionic‐liquid based aqueous biphasic systems [22]. IgY‐PEG 
6000 can be extracted by using three consecutive precipitation steps: 3.5, 8.5, and 12% is a 
recent adaptation to Polson et al. [17] technique and produces a high amount of specific egg 
yolk antibodies [23].
Proteins can be precipitated with sodium sulfate (Na
2
SO
4
, NaS) or ammonium sulfate [(NH
4
)
SO
4
, AmS]. Since the precipitation of certain proteins from a mixture by NaS or AmS depends 
on the concentration of the salt, this procedure can be used not only for isolation of desired 
proteins but also for elimination of the undesired ones. A precipitate is obtained through 
centrifuging, taken up in a certain amount of desired buffer or distilled water, and finally 
dialyzed [1]. NaS and AmS precipitations are economical and environmentally correct pro‐
cedures for yolk antibody extraction [24]. The major problem in separating IgY is to remove 
the high concentrations of lipids in egg yolk, which can be obtained by water dilution method 
[15], followed by IgY salt‐based precipitation in the antibody‐enriched fraction [25]. NaS or 
AmS precipitation provides fractions with low protein content compared to original yolk, but 
with a high specific activity [26]. Salt‐based yolk antibody precipitation is promising to be a 
more efficient and useful purification method for the large‐scale IgY from egg yolk prepara‐
tion [16, 27].
The isolation of IgY from yolk using of combination of different methods results in a high 
amount of specific antibodies with elevated purity. Sequential precipitation with 31% ammo‐
nium sulfate and 12% polyethylene glycol (PEG) produces IgY antibodies with above 95% 
purity and there is no loss in immunoreactivity [28]. The salt‐based egg antibody precipita‐
tion combined with thiophilic acid chromatography provides a simple and efficient mean of 
IgY from egg yolk [29, 30]. Association between AmS and ethanol to IgY precipitation results 
in a high quantity of antibodies with great purity [31]. Specific antisnake venom IgY with 
neutralizing effect for therapeutic proposes can be isolated by AmS precipitation followed 
to ion exchange chromatography [32, 33]. The inhibiting growth activity of IgY anti‐Strepto‐
coccus mitis was preserved by extracting yolk antibodies by precipitation with PEG 6000 and 
AmS and further isolation by DEAE cellulose ion exchange column chromatography [34]. 
Similarly, growth inhibition of Staphylococcus aureus and Escherichia coli was obtained with 
yolk antibodies isolated by NaS and AmS precipitations [35].
2.3.3. Isolating IgY by gel filtration
The separation of IgY antibodies according to their molecular weight through gel filtration is 
a further stage of purification of yolk antibodies but rarely reported except in the desalting of 
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preparation through columns instead through a dialysis [1]. Gel filtration by Sephacryl S300 
and Sephadex G50 or G75 provides a high‐purity IgY separation but further protein concen‐
tration procedures for separated antibody samples are desired [16, 36, 37]. On the other hand, 
the ion‐exchange chromatography is a widespread method to separate proteins from mix‐
tures and it is also used for immunoglobulins isolation. IgY antibodies are bound electrostati‐
cally to an ion‐exchange matrix with a reverse charge. According to the strength of binding, 
the antibodies are detached by increasing concentrations of ions of the buffers [1, 32, 33, 34].
2.3.4. Isolating IgY by affinity chromatography
The isolation of yolk IgY antibodies by affinity chromatography consist in attach an antibody 
ligand on a matrix. The extraction of mammalian IgG‐isotypes by affinity chromatography 
can be obtained by immobilized S. aureus A protein or B protein from the Streptococci of the 
C‐ or G‐group. IgY antibodies bind neither with protein A nor with protein G [1]. Recently, 
protein M (a transmembrane protein from human mycoplasma) has been demonstrated as 
a promising ligand for purifying polyclonal, monoclonal, or engineered IgY antibodies [38]. 
Synthetic IgY‐ligands were developed to improve yolk antibody isolating mainly by reduc‐
ing the purification steps and increasing the amount and purity of recovered IgY [39, 40]. 
Attaching the IgY‐induced antigen to matrix provides another way to extract a high‐purity 
IgY by affinity chromatography [41, 42]. The chromatographic thiophilic interaction provides 
a simple one‐step method capable of recovering IgY at concentration close to 100% of initial 
yolk antibody amount [29, 43].
2.4. IgY applications
2.4.1. Proteomic
IgY antibodies are suitable for a wide application protocols like proteomic, diagnostics, and 
therapy. The immunodepletion for humans or animal fluids by using specific IgY‐attached 
columns enables the detection of new protein spots, increases resolution, and highly improves 
the intensity of low‐abundance proteins by two‐dimensional polyacrylamide gel electropho‐
resis (2D‐PAGE) [44, 45]. Other possibility for the use of IgY to proteomic studies is screening 
random peptide phage display library to detect new epitope candidates to be applied for 
diagnostic methods to widespread parasitic human diseases [46]. Additionally, using phage‐
displayed chicken single‐chain antibody fragment libraries provides useful diagnostic and 
research reagents. Libraries constructed, using mRNA from an immune source, are enriched 
in affinity‐matured sequences. Repertoires focused on a number of defined targets can be 
constructed using lymphocyte mRNA from chickens immunized with a mixture of several 
different antigens from Plasmodium falciparum, Trypanosoma sp., or human viruses [47, 48].
2.4.2. Immunoassay
Development of IgY‐based immunoassay is a widespread field to apply yolk antibodies. 
Enzyme‐linked immunosorbent assay (ELISA), western blotting (WB), immunofluorescence 
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(IF), and immunohistochemistry (IHC) methods are the most common applications for IgY 
[1]. Relevant to consider that antigenic targets recognition by the use of antibodies can show 
some differences according to the method used. Regarding the conformational epitope struc‐
ture, the performance of antibodies recognizing a given epitope by WB can represent nothing 
about the same antibody performance in ELISA with the same antigen [49]. IgY antibody 
shows advantages comparing to the mammal IgG use in immunoassay. In this context, the 
rheumatoid factor (RF) is a major source of interference in many immunoassays using mam‐
malian polyclonal or monoclonal antibodies by interacting with IgG and causing false‐posi‐
tive results. IgY antibodies do not react with RF avoiding false‐positive results in ELISA [50].
2.4.2.1. Enzyme‐linked immunosorbent assay
IgY‐based ELISA does not demand expressive modifications from the most common proce‐
dures and reagents used to carry out this protocol [16, 51]. Egg yolk IgY can be labeled with 
horseradish peroxidase for use in immunoenzymatic assays [52]. Some possibilities for appli‐
cation of yolk antibodies‐based ELISA are: screening molecules related to drug‐drug inter‐
actions [53]; sandwich ELISA to capture bacterial toxins [54]; screening animal diseases by 
using recombinant antigens [55]; characterization of maternal IgY transferred to egg yolk [56]; 
coproantigen to capture ELISA for intestine human parasite [57]; screening antibiotic residues 
in food samples [58]; detection of blood circulating helminth antigens by immunomagnetic 
bead ELISA [59]; potential for clinical application diagnosing cancer antigen [60].
2.4.2.2. Immunofluorescence assay
IgY antibodies can be applied to immunofluorescence and flow cytometry assays. IgY‐based 
immunofluorescence experiment allows the detection of antigenic targets on cells and tis‐
sues samples [61]. Considering that IgY antibodies do not induce Fc‐dependent activation of 
complement, they must be used to clarify the pathogeny of mammalian autoimmune diseases 
by immunofluorescence assay [62]. Chicken IgY and rabbit IgG conjugations with fluorescein 
isothiocyanate (FITC) comparatively used to examine strains of Campylobacter fetus revealed 
that both conjugates have a high percentage rate of detection; IgY has less background due to 
unspecific fluorescence than IgG. Additionally, IgY is a cheap, bloodless, and very productive 
method [63]. FITC‐labeled anti‐Mycobacterium avium subspecies paratuberculosis can target the 
pathogen inside the cytoplasm of infected macrophages [64]. Frozen liver fragments were 
diagnosed with cytomegalovirus antigens by using IgY‐based confocal microscopy confirm‐
ing the yolk antibody as suitable reagent for immunofluorescence assay [65].
2.4.2.3. Flow cytometry assay
IgY antibodies are suitable reagents for flow cytometry and as well as certain monoclonal anti‐
bodies, for example, to study human and rabbit platelet physiology [66]. When using phage 
display‐based single chain variable fragments (scFvs), polyclonal IgY production and further 
the flow cytometry assays it is possible to develop immunoreagents for the isolation and char‐
acterization of stem cells, molecular diagnostics and therapeutics of lung cancers [67, 68].
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2.4.2.4. Immunochromatographic assay
The immunochromatographic assay (ICA) requires no instruments and has a detection time 
of less than 10 minutes and it is portable and easy to perform in the field. The development 
of IgY‐based strip could be a promising on‐site tool for screening infection or disease out‐
breaks. IgY‐gold complexes depositing onto the conjugate pad as detector reagents showed 
high specificity [69, 70].
2.4.2.5. Using IgY for passive immunization
The passive immunization is a protective method, which has been tested for many years and 
shown to be effective [71]. Passive immunization with pathogen‐specific egg yolk antibodies 
(IgY) is emerging as a potential alternative to antibiotics for the treatment and prevention of 
several human and animal diseases. Laying hens are an excellent source of high‐quality poly‐
clonal antibodies, which can be collected noninvasively from egg yolks. The use of IgY offers 
several advantages such as it is environmentally friendly, nontoxic, reduces the numbers of 
animals required for antibody production, stability in the orogastrointestinal tract, and its 
safety profile [71–74]. A major obstacle to its implementation is its relatively high cost, which 
is dependent, among other things, mainly on two factors: the efficacy of antibody production, 
and the use of specific pathogen‐free (SPF) birds for antibody production to avoid the possible 
of pathogens transference from commercial layers. Alternatively, treatment of the extracted 
IgY with formalin can negate the need for SPF birds and shows no interference with the Fab 
specific antigen‐binding or Fc‐complement activation of the antibody [75].
Regarding the IgY concentration in egg yolk and blood of laying hens, a recent study provides 
evidence that there is a significant circaseptan rhythm in yolk IgY and circaquattran rhythm 
in serum IgY. Additionally, the serum IgY concentration reached to maximum in the morn‐
ing, decreased to minimum during the daytime, and increased again at night revealing a 
significant circadian rhythm, which may reflect in yolk antibody concentration [76].
The microencapsulation with a methacrylic acid copolymer may be an effective method of 
protecting purified yolk IgY from gastrointestinal inactivation, enabling its use for oral pas‐
sive immunotherapy [77]. The use of chitosan‐alginate microcapsules to protect IgY from gas‐
trointestinal environment conditions provides significant resistance to pepsin hydrolysis and 
may enable intact IgY to reach target microorganisms within the lower digestive tract [78]. 
Another approach protecting IgY from degradation in gastric pH can be the incorporation of 
antibodies to hydrogel containing acrylamide and acrylic acid with promising results for IgY 
oral delivery [79].
Oral administration of IgY antibodies has been tested for many years with promising results 
[80] to different pathogens as human rotavirus [81]; dental plaque formation by Streptococcus 
mutans [82, 83]; enteropathogenic E. coli [84]; Helicobacter pylori [85, 86]; Cryptosporidium par‐
vum [87, 88]; canine parvovirus [89]; Porphyromonas gingivalis [90]; Pseudomonas aeruginosa 
[91]; shrimp’s white spot syndrome virus [92]; Eimeria acervulina [93]; E. tenella and E. max‐
ima [94, 95]; H5N1 e H1N1 in mice [96]; Vibrio cholerae [97]; rotavirus and norovirus [98]; 
Campylobacter jejuni [99–101]; and botulinum neurotoxins [102]. Immunotherapy as a  passive 
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immunization method to neutralize venom using purified IgY proved to be efficient for ther‐
apy protocol [103–107].
2.5. State of art the use of IgY for Toxoplasma gondii studies
Currently, there are a limited number of studies about IgY antibody production against 
T. gondii, either native or recombinant antigens. T. gondii is a worldwide public health and 
veterinary problem.
Hassl et al. [108] first described the production of anti‐T. gondii IgY. They used total soluble 
antigens that are immunogenic to comparatively produce rabbit IgG and chicken IgY. The 
results indicated differences between the specificities of egg yolk IgY antibodies and rabbit 
IgG serum antibodies, although both animal species had been immunized with identical anti‐
gen preparations. Ferreira Junior et al. [16] have produced comparative mice IgG and chicken 
IgY against soluble antigens from tachyzoites of T. gondii. They purified yolk antibodies by 
water dilution method, sodium sulfate precipitation, and molecular weight exclusion chro‐
matography. Specific antibody characterization was due to both indirect ELISA and Western 
blotting methods and applied to immunofluorescence assays by immunohistochemistry and 
immunocytochemistry assays. Using the Western blotting method, the antigenic bands rec‐
ognition profile were different between mice and chicken antibodies. IgY antibodies detected 
parasites in cytoplasm of infected cells and in brain samples of infected mice.
Hoto et al. [109] experimentally infected turkeys with tachyzoites and oocyst, and chickens 
with oocyst from T. gondii and investigated the humoral response against recombinant T. gon‐
dii antigens (rGRA1, rGRA6, rGRA9, rSAG1, and r SUB1) in a line blot assay. They found that 
infection with oocyst induced a stronger, permanent long‐lasting antibody response com‐
pared to tachyzoite‐infected animals.
Studying the heat shock protein of T. gondii (TgHSP70), a parasite virulence factor that is 
expressed during parasite stage conversion, Barenco et al [110] produced a polyclonal IgY 
against the recombinant TgHSP70 and tested it to detect native heat shock protein in brain 
samples from T. gondii‐infection resistant (BALB/c) and susceptible (C57BL/6) mice after dexa‐
methasone (DXM)‐induced infection reactivation. In parallel, they investigated the TgHSP70‐
specific humoral response. They found higher specific antibody titers in serum samples of 
BALB/c compared with C57BL/6 mice. C57BL/6 mice presented high expression of TgHSP70 
in the brain with the progression of infection and under DXM treatment. They conclude that 
these data suggest that the TgHSP70 release into the bloodstream depends on the death of the 
parasites mediated by the host immune response, whereas the increased TgHSP70 expression 
in the brain depends on the multiplication rate of the parasite.
More recent study with IgY and T. gondii was published by Cakir‐Koc [111]. In this investiga‐
tion, specific IgY antibodies were produced against the surface antigen 1 (SAG1) protein of 
T. gondii and the antibody activity was carried out by ELISA. Specific and higher amounts of 
IgY antibody against SAG1 were obtained. Regarding the advantages of IgY antibody and the 
importance of SAG1 for the diagnosis of toxoplasmosis, anti‐SAG1 IgY would be a promising 
reagent in research, diagnostics, and immunotherapy against toxoplasmosis.
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2.6. Future perspectives for the use of IgY for Toxoplasma gondii investigations
Although there are a reduced number of papers with IgY and T. gondii, the yolk IgY anti‐
body has been demonstrated as an efficient tool for application for various kinds of differ‐
ent methods. Regarding phylogeny distance between chicken and mammals, which reflects 
differences in antigens profile recognition, IgY technology may be applied for the screening 
of new antigen libraries by random phage display method and the selection of candidate 
targets for therapy, diagnostics, or vaccine. In this context, polyclonal IgY and scFvs may 
be a promising alternative for proteomic studies. In the field of diagnostic methods, yolk 
IgY might be used as an alternative to mammalian IgG for rapid test to detect phase dis‐
ease‐associated circulating antigens, ELISA, flow cytometry test, and fluorescence tech‐
niques. Enzyme‐labeled or fluorophore‐labeled IgY as a primary antibody is employed 
to detect T. gondii antigens in fixed tissue samples or parasite‐cultured cells. Speculating 
about a possible therapy for oral infection by T. gondii, IgY protecting the definitive and 
the intermediary hosts against infection may be an efficient tool for public health to control 
human and animal toxoplasmosis.
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